FAM222A

Across TCGA pan-cancer cohorts, FAM222A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FAM222A data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FAM222A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM222A expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where FAM222A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.628	0.959	.001	21	view →
LSCC	DFS	Tertile	All	1.000	0.868	<.001	17	view →
PDAC	DFS	Tertile	II,III,IV	0.170	0.528	.017	15	view →
HNSC	OS	Median	All	0.799	0.937	.001	9	view →
LUAD	DFS	Median	All	0.872	0.961	.020	5	view →
GBM	OS	Median	All	0.559	0.278	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FAM222A–CCRCC (DFS)

Open the CCRCC breakdown →